Edison Investment Research - Condor Gold (CNR) Update: Termination of coverage

Report

Edison Investment Research

Update: Termination of coverage

Edison Investment Research is terminating coverage on Condor Gold (CNR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

21/10/2014 1 EN

Underlying

Condor Gold

Condor Gold is engaged in identifying, acquiring, developing and divesting investments of gold and silver mineral concessions. Co., at the end of Dec 31 2016, had 100.0% ownership of 10 concessions in the La India Mining District and a further four in four project areas in Nicaragua. Co. is investing in the La India Project, which is a concession package covering an estimated 98.0% of the La India Gold Mining District. Co. also has investments in the Boaco Project, RAAN Project, and Nueva Segovia Project.

See profile

GB00B8225591 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast 21 07 2023

*A corporate client of Hybridan LLP ** Arranged by most recent first *** Alphabetically arranged Dish of the day Joiners: No joiners today. Leavers: Star Phoenix Group (STA.L) has left AIM. What’s cooking in the IPO kitchen?** Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Blackpoint Biotech plc, a medical cannabinoids company established...

July 21, 2023 July 21, 2023 1 EN

EQS Group AG

EQS-News: Condor Gold entertaining potential buyers for La India gold project

EQS-News: Condor Gold PLC Condor Gold entertaining potential buyers for La India gold project 30.11.2022 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 30.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Language...

November 30, 2022 November 30, 2022 1 EN

GlobeNewsWire

Mineral Resource Update for La India Project of 9.7 Mt at 3.5 g/t gold for 1,088,000 oz gold in the Indicated Category and 8.8 Mt at 4.3 g/t gold for 1,190,000 oz gold in the Inferred Category

Mineral Resource Update for La India Project of 9.7 Mt at 3.5 g/t gold for 1,088,000 oz gold in the Indicated Category and 8.8 Mt at 4.3 g/t gold for 1,190,000 oz gold in the Inferred Category GODALMING, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Condor Gold (AIM: CNR; TSX: COG) is pleased to announce the results of an updated Mineral Resource Estimate (the “MRE”) on its 100% owned La India Project in Nicaragua. The updated MRE is 9,672 kt at 3.5g/t gold for 1,087,000 oz gold in the indicated mineral resource category and 8,642 kt at 4.3 g/t gold for 1,189,000 oz gold in the inferr...

August 17, 2022 August 17, 2022 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

22h 22h 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN